HT

A group of journalists from HT investigates the impact of Fukushima's controversial plan to dump water into the ocean

Retrieved on: 
Thursday, November 24, 2022

A group of international journalists led by Global Think Agency investigates and analyzes the impact of the controversial plan to discharge water from Fukushima into the sea.

Key Points: 
  • A group of international journalists led by Global Think Agency investigates and analyzes the impact of the controversial plan to discharge water from Fukushima into the sea.
  • It is currently unknown how the long-lived radioactive isotopes contained in the contaminated water will interact with marine biology, this situation is "unprecedented".
  • Tepco is also accused of irresponsibly delaying the cooling of the reactors with salt water because it was going to ruin them beyond repair.
  • HT is a global agency specializing in developing documentary, research and entertainment content.

Humantelligence Named Best In Class HR Technology for Culture & Collaboration by HRO Today Association

Retrieved on: 
Tuesday, November 22, 2022

"It's important to empower employees with the kind of tools that enable more effective collaboration. We know that when people better understand themselves and others, they can better connect with each other, become more deeply engaged in their work and perform better. At the same time, organizations can increase productivity and improve the employee experience -- it's a win-win for everyone. In our work with hundreds of organizations, we've seen our collaboration tool change the way companies think about how people work together, and it's really gratifying to be recognized by HRO Today for this work," said Humantelligence's CEO, Juan Betancourt.

Key Points: 
  • Humantelligence (HT) won the 2022 HRO Today Association Award for Best In Class HR Technology, recognizing its one-to-one and team collaboration technology for its ease of use, quick implementation, and ability to optimize collaboration on the spot for remote and hybrid teams.
  • MIAMI, Nov. 22, 2022 /PRNewswire-PRWeb/ -- Humantelligence (HT) won the 2022 HRO Today Association Award for Best In Class HR Technology in the North America region at last week's HRO Today Association Conference -- attended by more than 150 senior HR executives.
  • This year, Humantelligence earned top technology honors by RemoteTech Breakthrough and TalentCulture for its team collaboration solution.
  • The HRO Today Association is the premier networking and content community for advancing the human resources profession.

Akoya Reports Record Revenue with 40% YoY Growth in the Third Quarter and Raises Full Year 2022 Revenue Guidance

Retrieved on: 
Monday, November 7, 2022

MARLBOROUGH, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2022.

Key Points: 
  • Total revenue was $18.9 million in the third quarter of 2022, compared to $13.5 million in the prior year period; an increase of 40%.
  • Product revenue was $14.4 million in the third quarter of 2022, compared to $10.9 million in the prior year period; an increase of 32%.
  • Services and other revenue totaled $4.4 million in the third quarter of 2022, compared to $2.6 million in the prior year period; an increase of 69%.
  • Gross profit was $10.9 million and gross profit margin was 58% in the third quarter of 2022.

Akoya Biosciences Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy

Retrieved on: 
Monday, November 7, 2022

MARLBOROUGH, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced the launch of PhenoCode™ Signature Panels for high-throughput spatial biomarker discovery and validation on the PhenoImager® platforms. Each of the customizable multiplex panels includes key markers for phenotyping the tumor microenvironment (TME) and immune status. When combined with the high-speed and robust imaging of the PhenoImager platforms, a rapid, quantitative, end-to-end spatial phenotyping workflow is enabled. The workflow accelerates development and validation of predictive signatures and prognostic biomarkers for immuno-oncology applications.

Key Points: 
  • The workflow accelerates development and validation of predictive signatures and prognostic biomarkers for immuno-oncology applications.
  • Poster presentations and a symposium describing the application of PhenoCode Signature Panels will be offered at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held in Boston, Massachusetts, November 8-12, 2022.
  • The PhenoCode Signature Panels provide our translational and clinical partners with a ready-made and customizable solution to rapidly advance their biomarker programs.
  • The PhenoCode Signature chemistry represents an important milestone in Akoyas commitment to create a suite of platform solutions from discovery to diagnostics.

Akoya to Participate at Three Upcoming Investor Conferences

Retrieved on: 
Thursday, November 3, 2022

MARLBOROUGH, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (Akoya), The Spatial Biology Company, today announced that it will be participating in three upcoming investor conferences.

Key Points: 
  • MARLBOROUGH, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (Akoya), The Spatial Biology Company, today announced that it will be participating in three upcoming investor conferences.
  • The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy.
  • Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler, PhenoImager Fusion and PhenoImager HT.
  • To learn more about Akoya, visit www.akoyabio.com .

HEXO Reports Q4’22 and FY22 Financial Results

Retrieved on: 
Tuesday, November 1, 2022

GATINEAU, Québec, Oct. 31, 2022 (GLOBE NEWSWIRE) -- HEXO Corp. (TSX: HEXO; NASDAQ: HEXO) ("HEXO" or the “Company"), a leading producer of high-quality cannabis products, today reported its financial results for the fourth quarter (“Q4’22”) and fiscal year ended July 31, 2022 ("FY22"). All currency amounts are stated in Canadian thousands unless otherwise noted.

Key Points: 
  • GATINEAU, Qubec, Oct. 31, 2022 (GLOBE NEWSWIRE) -- HEXO Corp. (TSX: HEXO; NASDAQ: HEXO) ("HEXO" or the Company"), a leading producer of high-quality cannabis products, today reported its financial results for the fourth quarter (Q422) and fiscal year ended July 31, 2022 ("FY22").
  • The fourth quarter was a period of strategic realignment for HEXO, said Charlie Bowman, President and CEO of HEXO.
  • Re-financing of the senior secured convertible note deleverage the balance sheet and boosted cash reserves, allowing us to focus on profitable growth, said Julius Ivancsits, Acting Chief Financial Officer of HEXO.
  • HEXO recorded net revenue in FY22 of $191.1 million, up from $123.8 million from the fiscal year ended July 31, 2021 (FY21).

CureApp: Digital Therapeutic App for Hypertension Receives Insurance Coverage, Sales of the Service to Medical Institutions Across Japan Launch on September 1

Retrieved on: 
Wednesday, November 2, 2022

Looking ahead, the app will be prescribed and provided to patients with hypertension as a health insurance treatment at medical institutions.

Key Points: 
  • Looking ahead, the app will be prescribed and provided to patients with hypertension as a health insurance treatment at medical institutions.
  • In April 2022, CureApp HT was the first digital therapeutics app for hypertension to receive government approval in the world, and the app has been covered by insurance since September 1.
  • This marks the first case of a DTx treatment solution being covered by insurance in the field of hypertension in the world.
  • Looking ahead, we will look to sequentially rolling out this Japanese-developed digital health solution worldwide based on the model established in Japan.

Hersha Hospitality Trust Closes the Sale of Hotel Milo Santa Barbara and Pan Pacific Seattle

Retrieved on: 
Tuesday, October 25, 2022

PHILADELPHIA, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Hersha Hospitality Trust (NYSE: HT) (“Hersha” or the “Company”), owner of luxury and lifestyle hotels in coastal gateway and resort markets, has closed on the previously announced sales of The Hotel Milo Santa Barbara and The Pan Pacific Seattle.

Key Points: 
  • Coupled with the USS-7 sale and pending dispositions, the sale of Hotel Milo and Pan Pacific would increase total sales to nearly $650M in 2022
    PHILADELPHIA, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Hersha Hospitality Trust (NYSE: HT) (Hersha or the Company), owner of luxury and lifestyle hotels in coastal gateway and resort markets, has closed on the previously announced sales of The Hotel Milo Santa Barbara and The Pan Pacific Seattle.
  • Mr. Jay H. Shah, Hershas Chief Executive Officer, stated, Were pleased to have closed these two previously announced dispositions.
  • We believe the pricing on these two assets reflects our realigned portfolios per key valuation and further highlights Hershas public-to-private market valuation disconnect.
  • Hersha Hospitality Trust (HT) is a self-advised real estate investment trust in the hospitality sector, which owns and operates luxury and lifestyle hotels in coastal gateway and resort markets.

Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study

Retrieved on: 
Monday, October 17, 2022

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline efficacy results from its Phase 1 / 2 clinical trial of DARE-HRT1. DARE-HRT1 is a novel, investigational intravaginal ring (IVR) designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy (HT) regimen. HT is used to treat the vasomotor symptoms (VMS) and genitourinary syndrome associated with menopause. DARE-HRT1 has the potential to be the first FDA-approved product to offer vaginal delivery of combination bio-identical estradiol and bio-identical progesterone hormone therapy in a convenient monthly format. The topline data from the study demonstrated improvement in both VMS as well as vaginal symptoms of menopause. The North American Menopause Society’s (NAMS) guidance on hormone therapy states that dosing estrogen and progestogen in combination may offer important benefits to women, and NAMS observed that non-oral routes of administration may offer advantages over orally administered therapies.

Key Points: 
  • SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Dar Bioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced positive topline efficacy results from its Phase 1 / 2 clinical trial of DARE-HRT1.
  • The topline data from the study demonstrated improvement in both VMS as well as vaginal symptoms of menopause.
  • These data support the potential of DARE-HRT1 to deliver effective hormone therapy in a 28-day intravaginal ring, said Dr. Annie Thurman, Medical Director of Dar Bioscience.
  • Dar plans to submit data from the Phase 1 / 2 clinical study of DARE-HRT1 for publication in a peer-reviewed publication.

We Eat Snacks With Our Eyes First - Colors Matter: HunterLab Launches Snack Food Campaign, Providing State-of-the-Art Spectrophotometers to Ensure Vibrant Food Hues and Color Tones

Retrieved on: 
Tuesday, October 18, 2022

RESTON, Va., Oct. 18, 2022 /PRNewswire/ -- HunterLab announced a multi-pronged snack food campaign from October 18 through January 10 to increase awareness of the importance of color quality in food. For over 70 years, HunterLab has helped products like chips/crisps, cheese puffs/balls, and roasted nuts keep reliably vibrant colors – allowing manufacturers to reproduce iconic brands perfectly and consistently with each batch. Inventors of the foundational Hunter L, a, b values used in global spectrophotometry, HunterLab provides the most innovative, user friendly, and full spectrum color-measurement technology for food production and many other industries.

Key Points: 
  • "Consistency of color is a vital concern to the food industry, with snack foods in particular," said Paul Barnes, Sales Manager of HunterLab.
  • "It's a well-studied fact that customers are drawn to bright, cheery colors in the supermarket.
  • Those colors remind us of nature and are usually associated with flavor, nutrition, and ripeness.
  • Color serves to satisfy a hard-wired function in our brain: we all know what spoiled food 'looks' like, and we gravitate toward the 'fresh.'